Abstract
The current basic and clinical studies of S-1 (TS-1®) were reviewed. S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FT) and two types of enzyme inhibitor; 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1 : 0.4 : 1. In pharmacokinetic studies, S-1 showed high 5-FU concentration in blood for long periods of time. In a combined analysis of two pivotal late phase II studies in gastric cancer, the overall response rate was 44.6% (45/101), and median survival time and 1-year survival rate were 244 days and 37%, respectively. A postmarketing survey was conducted, and in the interim analysis, tolerability and safety profiles were shown in 3294 patients with gastric cancer. The oral dose form and low incidence of adverse reactions permit treatment on an outpatient basis. To evaluate the survival benefit of S-1 in advanced gastric cancer, a phase III study of S-1 vs 5-FU vs cisplatin (CDDP) plus irinotecan (CPT-11) has been conducted. The effect of S-1 in adjuvant chemotherapy is also promising. Currently, a phase III study of surgery alone vs S-1 in patients with curative resection of gastric cancer is in progress. Further therapeutic benefits are expected to be gained by combining S-1 with other chemotherapeutic agents. Several preliminary results of combination phase I/II studies of S-1 with CDDP or CPT-11 have recently been obtained, and phase II studies are in progress. Thus, S-1 is currently the first candidate as the standard anticancer drug for gastric cancer. Further evaluations by well-controlled clinical trials are still needed.
Article PDF
Similar content being viewed by others
References
JL Grem (2000) ArticleTitle5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development Invest New Drugs 18 299–313 Occurrence Handle11081567 Occurrence Handle10.1023/A:1006416410198 Occurrence Handle1:CAS:528:DC%2BD3cXotFCqurc%3D
Meta Analysis (1998) ArticleTitleGroup in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced cancer J Clin Oncol 16 301–8
Meta Analysis (1998) ArticleTitleGroup in Cancer. Toxicity of fluorouracil in patients with advanced gastric cancer: effect of administration schedule and prognostic factors J Clin Oncol 16 3537–41
T Moynihan R Hansen T Anderson E Quebbeman P Beatty R Ausman et al. (1998) ArticleTitleContinuous 5-fluorouracil infusion in advanced gastric carcinoma Am J Clin Oncol 11 461–4
T Shirasaka Y Shimamoto H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
H Toide H Akiyoshi Y Minato H Okuda S Fujii (1977) ArticleTitleComparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil Gann 68 553–60 Occurrence Handle22472 Occurrence Handle1:CAS:528:DyaE1cXhsVGrtb4%3D
S Fujii Y Shimamoto H Ohshimo T Imaoka M Motoyama M Fukushima et al. (1989) ArticleTitleEffects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats Jpn J Cancer Res 80 167–72 Occurrence Handle2498251 Occurrence Handle1:CAS:528:DyaL1MXhvVGmsr0%3D
S Fujii S Kitano K Ikenaka M Fukushima T Shirasaka (1979) ArticleTitleCo-administration of uracil or sytosine on antitumor activity of FT207 or 5-FU derivatives Jpn J Cancer Chemother 6 1097–103
H Takiuchi JA Ajani (1998) ArticleTitleUracil-Tegafur in gastric carcinoma: a comprehensive review J Clin Oncol 16 2877–85 Occurrence Handle9704742 Occurrence Handle1:CAS:528:DyaK1cXlsFCnsr0%3D
J Carmichael T Popiela D Radstone S Falk M Borner A Oza et al. (2002) ArticleTitleRandomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3617–27 Occurrence Handle12202662 Occurrence Handle10.1200/JCO.2002.10.129 Occurrence Handle1:CAS:528:DC%2BD38XntVynsrs%3D
JY Douillard PM Hoff JR Skillings P Eisenberg N Davidson P Harper et al. (2002) ArticleTitleMulticenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 3605–16 Occurrence Handle12202661 Occurrence Handle10.1200/JCO.2002.04.123 Occurrence Handle1:CAS:528:DC%2BD38XntVynsro%3D
K Tatsumi M Fukushima T Shirasaka S Fujii (1987) ArticleTitleInhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748–55 Occurrence Handle3114201 Occurrence Handle1:CAS:528:DyaL2sXlvFSntL8%3D
T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka et al. (1996) ArticleTitleAntitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602–6 Occurrence Handle8653704 Occurrence Handle1:CAS:528:DyaK28XjtlCgurg%3D
T Takechi A Fujioka E Matsushima M Fukushima (2002) ArticleTitleEnhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyrimidine (CDHP) in human tumour cells Eur J Cancer 38 1271–7 Occurrence Handle12044515 Occurrence Handle10.1016/S0959-8049(02)00048-5 Occurrence Handle1:CAS:528:DC%2BD38XktVeitLY%3D
H Foenig A Patel (1970) ArticleTitleBiochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate Arch Neurol 23 155–60
A Sobrero D Kerr B Glimelius EV Cutsem G Milano DM Pritchard et al. (2000) ArticleTitleNew directions in the treatment of colorectal cancer: a look to the future Eur J Cancer 36 559–66 Occurrence Handle10738119 Occurrence Handle10.1016/S0959-8049(99)00314-7 Occurrence Handle1:CAS:528:DC%2BD3cXitVSns7s%3D
T Shirasaka Y Shimamoto M Fukushima (1993) ArticleTitleInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004–9 Occurrence Handle7689420 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsrk%3D
T Kato Y Shimamoto J Uchida H Ohshimo M Abe T Shirasaka et al. (2001) ArticleTitlePossible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil Anticancer Res 21 1705–12 Occurrence Handle11497250 Occurrence Handle1:CAS:528:DC%2BD3MXmt1eru7g%3D
M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi et al. (1998) ArticleTitlePreclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693–8 Occurrence Handle9735397 Occurrence Handle1:CAS:528:DyaK1cXmsVClurw%3D
T Taguchi Y Inuyama R Kanamaru K Hasegawa S Akazawa H Niitani et al. (1997) ArticleTitlePhase I study of S-1 Jpn J Cancer Chemother 24 2253–64 Occurrence Handle1:STN:280:DyaK1c%2Fotl2rug%3D%3D
K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi et al. (1999) ArticleTitleAn early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers Oncology 57 202–10 Occurrence Handle10545788 Occurrence Handle10.1159/000012032 Occurrence Handle1:CAS:528:DyaK1MXmvF2msr0%3D
A Ohtsu H Baba Y Sakata Y Mitachi N Horikoshi K Sugimachi et al. (2000) ArticleTitlePhase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma Br J Cancer 83 141–5 Occurrence Handle10901361 Occurrence Handle1:CAS:528:DC%2BD3cXltl2mur8%3D
T Taguchi K Morimoto N Horikoshi S Takashima T Toge M Kimura et al. (1998) ArticleTitleAn early phase II clinical study of S-1 in patients with breast cancer Jpn J Cancer Chemother 25 1035–43 Occurrence Handle1:STN:280:DyaK1czgvVWruw%3D%3D
Y Inuyama A Kida M Tsukuda N Kohno B Satake (1998) ArticleTitleEarly phase II study of S-1 in patients with advanced head and neck cancer Jpn J Cancer Chemother 25 1151–8 Occurrence Handle1:STN:280:DyaK1czksVGhsg%3D%3D
K Furuse M Kawahara K Hasegawa S Kudoh M Takada T Sugiura et al. (2001) ArticleTitleEarly phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer Int J Clin Oncol 6 236–41 Occurrence Handle11723745 Occurrence Handle1:CAS:528:DC%2BD3MXovVGhtrw%3D
Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
H Niitani M Kurihara T Saito I Nakao O Abe I Urushizaki et al. (1985) ArticleTitlePhase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer — multi-institutional cooperative study Jpn J Cancer Chemother 12 2044–51 Occurrence Handle1:STN:280:BimD38vjt1w%3D
K Ishibiki K Kumai S Kodaira O Abe K Yamamoto T Ouchi et al. (1989) ArticleTitlePhase II study with cisplatin in advanced stomach and colon cancer Jpn J Cancer Chemother 16 3185–93 Occurrence Handle1:STN:280:BiaA1M7ltlI%3D
K Futatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada et al. (1994) ArticleTitleLate phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer Jpn J Cancer Chemother 21 1033–8 Occurrence Handle1:STN:280:ByuB2s%2FotFQ%3D
T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ota et al. (1998) ArticleTitleLate phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperatative Study Group Trial (Group A) Jpn J Cancer Chemother 25 1915–24 Occurrence Handle1:STN:280:DyaK1M%2FhsVGnug%3D%3D
M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota et al. (1999) ArticleTitleA late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperatative Study Group Trial (Group B) Jpn J Cancer Chemother 26 487–96 Occurrence Handle1:STN:280:DyaK1M7pslyiug%3D%3D
K Yamaguchi M Tada N Horikoshi T Otani H Takiuchi S Saitoh et al. (2002) ArticleTitlePhase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90–5 Occurrence Handle12111584 Occurrence Handle10.1007/s101200200015 Occurrence Handle1:CAS:528:DC%2BD38XmslGlsbg%3D
Y Yamada K Shirao A Ohtsu N Boku I Hyodo H Saitoh et al. (2001) ArticleTitlePhase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis of paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133–7 Occurrence Handle11583196 Occurrence Handle10.1023/A:1011680507956 Occurrence Handle1:STN:280:DC%2BD3MrjsFehtQ%3D%3D
K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki et al. (2000) ArticleTitlePharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000–5
K Yamada Y Shirao K Matsumura M Muro T Goto Y Hamaguchi et al. (2001) ArticleTitleComparison of 5-fluorouracil and F-β-alanin pharmacokinetics in patients receiving protracted venous infusion of 5-fluorouracil and oral S-1 (abstract) Proc Am Soc Clin Oncol 20 91a
A Ohtsu N Boku F Nagashima W Koizumi S Tanabe K Saigenji et al. (2001) ArticleTitleA phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (ACG) (abstract) Proc Am Soc Clin Oncol 20 165a
H Narahara H Takiuchi T Tsujinaka H Furukawa T Taguchi (2002) ArticleTitlePhase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer (abstract) Proc Am Soc Clin Oncol 21 170a
Y Komatsu H Takeda T Masaaki T Kato M Tateyama T Miyagishima et al. (2002) ArticleTitleA phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC) (abstract) Proc Am Soc Clin Oncol 21 171a
Nagashima F, Ohtsu A, Boku N, Yoshida S, Itoh K, Sano M. Japanese nation-wide post marketing survey of S-1 in patients with advanced gastric Cancer. 4th International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, September 6–8, 2001, Koln, Germany
M Ikeda H Furukawa H Imamura J Shimizu H Ishida S Masutani et al. (2002) ArticleTitlePharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function Cancer Chemother Pharmacol 50 25–32 Occurrence Handle12111108 Occurrence Handle10.1007/s00280-002-0457-z Occurrence Handle1:CAS:528:DC%2BD38XkvVagu70%3D
T Yoshikawa M Kanari A Tsuburaya O Kobayashi M Sairenji H Motohashi et al. (2000) ArticleTitleAdvanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy Gastric Cancer 3 171–5 Occurrence Handle11984733
E Kurakawa I Kasuga S Ishizuka T Yoshida A Kunisawa K Minemura et al. (2001) ArticleTitleInterstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report Jpn J Clin Oncol 31 284–6 Occurrence Handle11463808 Occurrence Handle10.1093/jjco/hye057 Occurrence Handle1:STN:280:DC%2BD3MvhsVGhug%3D%3D
Y Tsukioka Y Matsumura T Hamaguchi M Goto K Muro Y Yamada et al. (2001) ArticleTitleComplete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report Jpn J Clin Oncol 31 450–3 Occurrence Handle11689601 Occurrence Handle10.1093/jjco/hye091 Occurrence Handle1:STN:280:DC%2BD3Mnjs1GntA%3D%3D
H Osugi N Takada M Takemura S Kaseno S Lee M Ueno et al. (2002) ArticleTitleOral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination Oncol Rep 9 811–5 Occurrence Handle12066214 Occurrence Handle1:CAS:528:DC%2BD38XltlGrsrk%3D
O Kobayashi K Konishi M Kanari H Cho T Yoshikawa A Tsuburaya et al. (2002) ArticleTitleUnusual survival for more than 2 years with peritoneal metastases of gastric cancer Gastric Cancer 5 47–50 Occurrence Handle12021860
T Iwazawa M Kinuta H Yano S Matsui S Tamagaki A Yasue et al. (2002) ArticleTitleAn oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection Gastric Cancer 5 96–101 Occurrence Handle12111585 Occurrence Handle10.1007/s101200200016
S Watanabe T Tanaka T Takeuchi H Takabayashi Y Hirayama (2002) ArticleTitleAdvanced gastric cancer with liver metastases successfully treated with S-1 Int J Clin Oncol 7 326–9 Occurrence Handle12402069
JA Ajani DM Ota DE Jackson (1991) ArticleTitleCurrent strategies in the management of locoregional and metastatic gastric cancer Cancer 67 260–5 Occurrence Handle1984825 Occurrence Handle1:STN:280:By6D1cvns1Q%3D
DL Schipper DJ Wagener (1996) ArticleTitleChemotherapy of gastric cancer Anticancer Drugs 7 137–49 Occurrence Handle8740718 Occurrence Handle1:CAS:528:DyaK28XjtF2ksbw%3D
M Tahara A Ohtsu (2000) ArticleTitleLatest progress on chemotherapy for advanced gastric cancer Jpn J Cancer Chemother 27 2048–58 Occurrence Handle1:STN:280:DC%2BD3M%2FntVCgsQ%3D%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maehara, Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6 (Suppl 1), 2–8 (2003). https://doi.org/10.1007/s10120-003-0232-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0232-9